On May 1, 2019 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, reported that it will report its first quarter 2019 financial results on Tuesday, May 7, 2019 (Press release, Iovance Biotherapeutics, MAY 1, 2019, View Source;p=irol-newsArticle&ID=2396513 [SID1234535493]). Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. EDT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 7393657. A live webcast can be accessed under "News & Events: Investor Calendar" in the Investors section of the Company’s website at www.iovance.com or at the link: View Source An archived webcast will be available in the Investors section of www.iovance.com for thirty days following the call.

On May 1, 2019 Physicians’ Education Resource (PER), a worldwide leading resource for continuing medical education (CME), reported that it will present an in-studio video broadcast titled, "Rapid Reviews in Oncology from Chicago: Practice-Changing Data in Breast Cancer" on Wednesday, June 19 at 8 p.m. EDT (Press release, Physicians’ Education Resource, MAY 1, 2019, View Source [SID1234535509]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live activity will be chaired by renowned breast cancer expert and leading clinical researcher Dr. Joyce O’Shaughnessy, who is the Celebrating Women Chair in Breast Cancer Research at Texas Oncology-Baylor Charles A. Sammons Cancer Center, and co-chair of the breast cancer research program at The US Oncology Network.

"We look forward to presenting this live-stream interactive broadcast to physicians after this year’s ASCO (Free ASCO Whitepaper) Annual Meeting to cover recent data in breast cancer," said Phil Talamo, president of PER. "PER’s Rapid Reviews in Oncology legacy program features highlights of practice-changing data in breast cancer, with expert faculty interpretation, along with audience Q&A sessions immediately following the Annual Meeting."

This live CME-certified interactive webcast is designed to rapidly update medical oncologists and fellows who treat patients with breast cancer with emerging data that has recently been presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting. O’Shaughnessy will be joined by a panel of experts who will highlight the implications and applications of these data for physicians’ practice, helping them optimize care for their patients with breast cancer. Attendees will also have the opportunity to learn how experts in breast cancer research place emerging data into clinical context for the treatment and management of patients with breast cancer and stay up-to-date on the latest data pertaining to treatment and management of breast cancer across the spectrum of disease.

This live webcast is accredited by the Accreditation Council for Continuing Medical Education for 2.0 AMA PRA Category 1 Credits for physicians. For more information and to register, click here.

On May 1, 2019 Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, reported that it will provide a clinical and business update before the U.S. markets open on Monday May 6, 2019 (Press release, Adaptimmune, MAY 1, 2019, View Source;p=RssLanding&cat=news&id=2396538 [SID1234535608]). Following the announcement, the Company will host a live teleconference and webcast with accompanying slides at 8:00 a.m. EDT (1:00 p.m. BST) on the same day (details below).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast Link for Clinical and Business Update Slide Presentation on May 6th
The Company will host a live teleconference and slide presentation at 8:00 a.m. EDT (1:00 p.m. BST) on Monday May 6, 2019. The live webcast of the conference call and slides will be available at View Source An archive will be available after the call at the same address. To participate in the live webinar, if preferred, please dial (833) 652-5917 (U.S. and Canada) or +1 (430) 775-1624 (International).

On May 1, 2019 DXC Technology (NYSE: DXC), the world’s leading independent, end-to-end IT services company, reported that it will release financial results for the fourth quarter of fiscal 2019 on Thursday, May 23, 2019, at approximately 4:15 p.m. Eastern Daylight Time (EDT) (Press release, DynPort Vaccine Company, MAY 1, 2019, View Source [SID1234535698]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

DXC Technology senior management will host a conference call and webcast on the same day at 5 p.m. EDT. The dial-in number for domestic callers is (888) 394-8218. Callers who reside outside of the United States should dial +1 (323) 794-2588. The passcode for all participants is 9706900. The webcast audio and any presentation slides will be available on DXC Technology’s Investor Relations website.

A replay of the conference call will be available from approximately two hours after the conclusion of the call until May 30, 2019. Replay numbers can be found at the following link. The replay passcode is also 9706900. A transcript of the conference call will be posted on DXC Technology’s Investor Relations website.

On May 1, 2019 MaxCyte, the global clinical-stage cell-based therapies and life sciences company, reported that Robert Keefe, Director of Technical Operations, provided an oral presentation on April 29, titled "Novel mRNA-based Autologous CAR Therapies in Oncology," at the annual meeting of the American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) in Washington, DC (Press release, MaxCyte, MAY 1, 2019, View Source [SID1234537622]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Keefe highlighted the CARMA platform’s key differentiating features, including manufacture and delivery to a patient in a fraction of the time compared to traditional chimeric antigen receptor (CAR) therapies and without a viral component. He also described the manufacturing feasibility data for MaxCyte’s first CARMA drug candidate, MCY-M11, a mesothelin-targeting chimeric antigen receptor (CAR), which is currently being evaluated in a Phase I clinical trial in mesothelin-expressing solid tumors at the National Cancer Institute (NCI) and Washington University in St Louis.

"The advancement of our first CARMA clinical trial, which is consistently showing the feasibility of our rapid manufacturing process, is significant for MaxCyte and the application of our technology," said Claudio Dansky Ullmann, MD, MaxCyte’s Chief Medical Officer. "Development of a cell therapy with application in solid tumors is impactful for patients with unmet needs in a variety of cancers and we look forward to further advancing this program."

The CARMA platform offers an innovative approach to cell-based therapies that can be applied in a broad range of diseases, including solid tumors. The manufacturing process for MCY-M11 utilizes MaxCyte’s proprietary Flow Electroporation technology to transfect mRNA into fresh (i.e., unexpanded) peripheral blood mononuclear cells (PBMCs). The entire CARMA manufacturing process allows for streamlined manufacturing providing a much needed faster turnaround of autologous cell therapy to patients. CARMA cell therapy was engineered with the intention of reducing potential adverse events that have been evident with other CAR technologies, and allowing for multiple dosing, a feature that may be key in the treatment of solid tumors with cellular therapies.

Last month, this trial was featured as a "trial in progress" at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting , via a poster highlighting key aspects of the study design.